Fish

Fish Adverse Event Insights

The FDA Center for Veterinary Medicine database holds 168 adverse event reports for Fish, distributed across 12 distinct breeds currently tracked in the system. Of those reports, 139 involved a death outcome — producing a 8270.0% case-fatality rate among reported events, which reflects reporting severity bias rather than true population mortality. These figures are aggregated directly from openFDA's Animal & Veterinary Adverse Events endpoint and update as new voluntary submissions flow through pet owners, veterinarians, and drug manufacturers.

The most frequently reported clinical signs for Fish are Death (91 reports), IGA Animal mortality greater than expected (41 reports), Fish body deformity (32 reports), Moribund (24 reports), with Death leading the reaction traffic at 91 submissions. On the product side, Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage) is the single most-referenced drug with 88 reports, followed by Florfenicol (34), Florfenicol Premix Pwd Aquacul (19), Atlantic Salmon Transgenic Whole (Opafp-Ghc2 Rdna Construct Inserted Into The A-Locus In The Eo-1A Lineage (7). This combination surfaces which therapeutic classes generate the most adverse event chatter for this species — a useful starting point when comparing Fish reporting patterns against other companion animals in the dataset.

Of the 179 Fish reports with a coded outcome, Died accounts for the largest share at 60.9%. Annual submission volume spans 2,010 to 2,025 reports across the 16 years on file, a range that reflects evolving owner awareness, veterinary reporting habits, and new product approvals rather than stable underlying incidence. The breed-level table below breaks these patterns down further, showing how the 12 tracked fish breeds compare on volume, deaths, and average age at report. As with all FDA adverse event data, correlation is the ceiling — causation requires clinical investigation beyond what these aggregates can provide.